Conference Abstract
 
Navigation
Conference Abstracts Index

Abstracts - 2006 London

Abstracts - 2005 Zurich

Abstracts - 2004 Berlin

Abstracts - 2003 Barcelona

Abstracts - 2002 Brussels

Abstracts - 2001 Tokyo

Abstracts - 2000 Marburg

       

P7.75 Clinical significance of the HLA-DR11 positive subset in patients with alopecia aerata

C. Marques Da Costaa, J.J. Stenea, E. Dupontb, M. Vandercruysb, M. Hidajatb,
M. Andrienb.

aDept. of Dermatology (St. Pierre Hosp.) and bImmunology (Erasme Hosp.) Université Libre de Bruxelles, Belgium

Many studies have shown an association of alopecia aerata (AA) with HLA-DR11. In view of the fact that in several autoimmune diseases such as psoriasis and diabetes, the existence of an HLA association indicates a clinical evolution (i.e. earlier onset of the disease) which is different from the forms that are not associated with HLA, we investigated various parameters in a group of 88 patients with severe AA. This included 32 DR11 positive and 56 DR11 negative patients. Compared to the frequency (22%) of DR11 in 99 healthy subjects belonging to the same ethnic background, a significant association (p = 0.01; RR =2.1) was found. However the analysis by DNA subtyping of the frequency of the various DR allotypes revealed a similar distribution in the diseased and in the control groups. In the DR11 positive subset, age of onset (16.4 ± 2.6 years) occurred significantly earlier than in the DR11 negative subset (27.3 ± 2.3 years ; p =        0.01). The analysis of the clinical course of patients was performed by considering two groups of patients, those with severe AU/AT forms and those not belonging to this peculiar subset. There was a slight although not significant excess of severe AU/AT cases in the DR11 pos group (n=17; 53%) as compared to the DR11 negative which included only 24 patients (43%).

It is concluded that the DR11 mediated form of AA includes patients with an earlier onset of disease, the later involving a slightly increased proportion of severe forms, an observation compatible with the existence of non HLA genes in addition to HLA genes in the development of the disease.